Flibanserin for Treating Hypoactive Sexual Desire Disorder

  • Sang J
  • Kim T
  • Kim S
N/ACitations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.

Cite

CITATION STYLE

APA

Sang, J. H., Kim, T.-H., & Kim, S. A. (2016). Flibanserin for Treating Hypoactive Sexual Desire Disorder. Journal of Menopausal Medicine, 22(1), 9. https://doi.org/10.6118/jmm.2016.22.1.9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free